Source: yahoo_news
Source ID: yahoo:5f1189a8ad8372ded74044131d6c3ad9:SXTP
URL: https://finance.yahoo.com/healthcare/articles/60-degrees-pharmaceuticals-announces-positive-120200927.html?.tsrc=rss
Symbol: (SXTP)
Published: 2026-07-01 08:02:00 EDT
Time precision: minute
Title: 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Independent DSMB identifies no safety concerns and recommends continuation of the clinical trial being conducted at the Icahn School of Medicine at Mount SinaiWASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chro